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Simple Summary: Proliferative verrucous leukoplakia is considered as an oral potentially malignant
disorder that presents the highest tendency to recurrence and malignant transformation, although
published diagnostic criteria are inconsistent. A precise evidence-based diagnosis is important to
differentiate this lesion from others on the oral mucosa with less tendency for cancer progression,
and thus establish specific management protocols aimed at the early diagnosis of oral cancer. In
this scoping review the published conceptual and diagnostic criteria for proliferative verrucous
leukoplakia were comprehensively analyzed, and a conceptual proposal for future diagnosis is
proposed based on current evidence.
Abstract: Proliferative verrucous leukoplakia (PVL) is considered as an oral potentially malignant
disorder (OPMD) that presents with a high tendency to recurrence after treatment and has the
highest malignant transformation ratio among all OPMD (50%). Evidence-based publications have
indicated that the malignant evolution reported is significantly related to the inconsistent diagnostic
criteria used in primary-level studies; so, it has been hypothesized that the risk of oral cancer for this
disease could even be underestimated. This is important because PVL requires specific management
protocols, evidence-based, aimed at the early diagnosis of cancer developing in these lesions. We
present a scoping review—a novel approach to mapping the available literature on a given topic
to provide an overview of the available research evidence and to highlight possible gaps in the
evidence—especially related in our study to the diagnostic aspects of PVL, and to issue a conceptual
proposal and diagnostic criteria for PVL. We conclude that PVL is a white, multifocal and progressive
lesion with a high malignant transformation rate which is diagnosed mainly around the age of
60 years without any specific histological characterization. We also advise a personal reflection on
the level of certainty with which the clinician makes the diagnosis of a particular case of PVL.
Keywords: proliferative verrucous leukoplakia; oral cancer; early diagnosis; diagnostic criteria;
scoping review
1. Introduction
The recent consensus meeting of the WHO Collaborating Center for Oral Cancer held
in Glasgow, Scotland in 2020 [1], focused on updating concepts and classification of oral
potentially malignant disorders (OPMD). Proliferative verrucous leukoplakia (PVL) was
classified as one of the important entities included among the wide range of conditions
considered as OPMDs. The Working Group defined PVL as a distinct form of multifocal
oral leukoplakia characterized by having a progressive clinical course, changing clini-
cal, and histopathological features and is associated with the highest proportion of oral
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cavity cancer development compared with other OPMD. The essential characteristics of
this OPMD are its recognized nature of recurrence on complete removal and high fre-
quency of development of oral carcinoma in comparison with other OPMDs [2]. Thus, in
a recent systematic review published in 2020, a malignancy transformation rate of 49.5%
(95% CI = 26.7–72.4%) has been reported [3]. An important consequence of this OPMD
is its marked tendency to evolve into multiple carcinomas, due to underlying field can-
cerization of the affected mucosa [4]. A subgroup of participants and collaborators at
the aforementioned consensus meeting were commissioned to update the information
regarding the malignant transformation rate of PVL and factors affecting it, which was
carried out through a systematic review and meta-analysis [5]. The results of this study
yielded a malignancy transformation rate of 43.87% (95% CI = 31.93–56.13). A remarkable
result of the Ramos-García et al. paper is related to the high variability of the malignancy
rates found in the studies included in this meta-analysis, which ranged between 0% [6] and
100% [7], and excluding these extreme values, between 14% [8] and 75% [9]. The analysis
of the reasons for this variability allowed us to point out the low methodological quality of
some of the 17 studies meta-analyzed in this paper [5]. Further analyses, after applying the
relevant sensitivity analyses, revealed that those studies with lower methodological quality
tended to report lower PVL malignant transformation rates (27.60%, 95% CI = 12.86–44.68).
Among the factors limiting the methodological quality of papers meta-analyzed by Ramos-
García et al. [5] were the criteria used by respective authors for the PVL diagnosis in their
original research and the short follow-up times reported. To date, four research groups
have proposed diagnostic criteria for PVL [10–13] (Table 1). In our opinion, the diagnostic
criteria used could influence the reported rate of PVL malignancy and most of the pro-
posed criteria could allow inclusion of lesions that are not really PVL [5] resulting in lower
malignant transformation rates. We believe that the absence of evidence-based diagnostic
criteria is at the origin of the variability of the PVL malignant transformation rates reported
in the literature.
In this study we present a scoping review—a novel approach for mapping available
literature on a given topic to provide an overview of the available research evidence and to
highlight potential gaps in the evidence [14,15]. Here we critically review the clinical and
histological aspects considered as the diagnostic criteria for PVL recommended in the four
proposals that have been published to date. We drew up a list of research questions derived
from the published diagnostic criteria. The aim of the study was to evaluate the extent
to which the authors adhered to the diagnostic criteria given in the original proposals
and whether low, intermediate, and high MT rates reflect adherence to the diagnostic
criteria selected by the authors. Our analysis allowed us to propose a concept for the future
diagnosis of PVL in which a minimum of evidence-based diagnostic criteria is implicit that
should be met to consider a white lesion as a PVL.
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Table 1. Diagnostic criteria published for proliferative verrucous leukoplakia (PVL).
CRITERIA/Conceptual Proposal Definitions or Proposal for PVL Diagnostic Criteria
Hansen et al. 1985 [10]
“ . . . specific form of leukoplakia. It began as a simple hyperkeratosis but tended to extend and become multifocal over varying periods of time. The lesions were
slow-growing, persistent, irreversible, and frequently developed erythematous components. Some areas later became exophytic and wart-like and transformed into
lesions that were clinically and microscopically identical to verrucous carcinoma and squamous cell carcinoma. In addition, they were resistant to every kind of therapy.”
Cerero-Lapiedra et al. 2010 [11]
Major Criteria (MC):
A. A leukoplakia lesion with more than two different oral sites, which is most frequently found in the gingiva, alveolar processes and palate.
B. The existence of a verrucous area.
C. That the lesions have spread or engrossed during development of the disease.
D. That there has been a recurrence in a previously treated area.
E. Histopathologically, there can be from simple epithelial hyperkeratosis to verrucous hyperplasia, verrucous carcinoma or oral squamous cell carcinoma, whether in
situ or infiltrating.
Minor Criteria (mc):
1. An oral leukoplakia lesion that occupies at least 3 cm when adding all the affected areas.
2. That the patient be female.
3. That the patient (male or female) be a non-smoker.
4. A disease evolution higher than 5 years.
Diagnosis of PVL:
1. Three major criteria (being E among them) or
2. Two major criteria (being E among them) + two minor criteria.
Carrard et al. 2013 [12]
1. Leukoplakia showing the presence of verrucous or wart-like areas, involving more than two oral subsites. The following oral subsites are recognized: dorsum of the
tongue (unilateral or bilateral), border of the tongue, cheek mucosa, alveolar mucosa or gingiva upper jaw, alveolar mucosa or gingiva lower jaw, hard and soft
palate, floor of the mouth, upper lip and lower lip.
2. When adding all involved sites, the minimum size should be at least three centimeters.
3. A well-documented period of disease evolution of at least five years, being characterized by spreading and enlarging and the occurrence of one or more recurrences
in a previously treated area.
4. The availability of at least one biopsy in order to rule out the presence of a verrucous carcinoma or squamous cell carcinoma.
Villa et al. 2018 [13]
1. White/keratotic lesions that may be smooth, fissured, verrucous, or erythematous with or without ulcer.
2. Multifocal non-contiguous lesions or a single large lesion >4.0 cm involving one site or a single large lesion >3 cm involving contiguous sites.
3. Lesions that progress/expand in size and/or develop multifocality over time.
4. Histopathology that, if not overtly exhibiting dysplasia or carcinoma, shows hyperkeratosis, parakeratosis, atrophy, or acanthosis with minimal to no cytologic
atypia (KUS), with or without a lymphocytic band, or verrucous hyperplasia; these features must not support a diagnosis of frictional or reactive keratoses
Proposal by Gonzalez-Moles et al. 2021 [5]
derived from the evidence obtained in this
scoping review
PVL is an oral potentially malignant disorder that presents in the form of multifocal white plaques, which have expanded throughout its evolution, persistent and resistant
to treatment, which is diagnosed in people in the second half of life, although it probably begins in earlier stages, and which has a very high risk of developing into oral
cancer.
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2. Materials and Methods
Since several non-evidence-based PVL diagnostic criteria have been published, a
scoping review design seems pertinent to rigorously synthesize evidence, guide future
research and make recommendations [14,15]. This scoping review closely followed the
Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping
Reviews (PRISMA-ScR) [16].
2.1. Protocol
Despite the lack of international consensus on the a priori design of study protocol of
a scoping review, in order to minimize risk of bias and improve the transparency, precision,
and integrity of our scoping review, a protocol on its methodology was designed (design
date: February 2021). A copy of the study protocol can be found as supplementary material
(File S1).
2.2. Search Strategy
PubMed, Embase, Web of Science, and Scopus databases were searched for studies
published before February 2021, with no lower date limit. In order to maximize sensitivity,
this search was conducted by combining the keywords “proliferative” and “verrucous”
and “leukoplakia”. Thesaurus terms (e.g., MeSH or Emtree) were not used due to the lack
of specific terms for the target disease (i.e., proliferative verrucous leukoplakia). We also
manually screened the reference lists of retrieved studies looking for additional relevant
studies and consulted experts in the field. All references were managed using Mendeley v.
1.19.4 (Elsevier. Amsterdam, The Netherlands); duplicate references were eliminated.
2.3. Eligibility Criteria
Following the Condition, Context and Population CoCoPop framework—designed
by Joanna Briggs Institute, University of Adelaide, Australia (Aromataris and Munn,
2020)—the following inclusion criteria were applied: studies investigating the malignant
transformation potential (condition) of subjects with PVL (population) diagnosed by clini-
cal and/or histopathological criteria (context), and their related characteristics (e.g., sex,
age, tobacco use, anatomical sites affected and age of the lesions, clinical course, resis-
tance to treatment, etc.), assessed through cohorts with follow up, without restrictions by
publication language or date.
The following exclusion criteria were applied: (1) studies not investigating PVL,
researching other types of OPMD or not reporting separated data on PVL; (2) studies
not researching the malignant transformation potential of PVL; (3) studies only focused
on gingival PVLs; (4) interventional studies, cross-sectional, case reports, reviews or
meta-analyses, personal opinions or commentaries, hypotheses, protocols, letters, posters,
meeting abstracts, and preclinical research (animal experimentation and in vitro studies);
(5) overlapping populations; when results were derived from the same study population,
we included the most recently reported or those providing more data; the use of the same
population in different studies was determined by verifying the name and affiliation of the
authors, source of patients, and recruitment period.
2.4. Study Selection Process
Eligibility criteria were independently applied by two authors (MAGM and PRG). Ar-
ticles were selected in two phases, first screening titles and abstracts for articles apparently
meeting inclusion criteria, and then reading the full text of selected articles, excluding those
that failed to meet the eligibility criteria. Any discrepancies were resolved by consensus.
The inter-agreement between evaluators on study eligibility was calculated using Co-
hen’s kappa (κ) statistic [17], obtaining an almost perfect agreement (99.41% of agreement,
κ = 0.96).
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2.5. Data Extraction
Two authors (MAGM and PRG) extracted data from the selected articles, complet-
ing a data collection form in a standardized manner using Excel and Word (v. 16/2018,
Microsoft. Redmond, WA, USA). Data expressed as order statistics (i.e., median, interquar-
tile range and/or maximum–minimum values) were computed and transformed into
means ± standard deviation (SD) using the methods proposed by Luo et al. (2018) and
Wan et al. (2014) [18,19]. If it was desirable to combine two different datasets expressed
as means ± SDs from subgroups into a single group, the formula provided by Cochrane
Handbook was applied [20]. Data were gathered on the first author, publication year,
country and continent, publication language, sample size, study design, recruitment and
follow up period, study design, diagnostic criteria, location of PVLs per patients (patients
were chosen as analysis units due to higher translational potential, not lesions), sex and
age of patients, tobacco and alcohol consumption. Finally, the data required to answer our
set of designed questions (see next section) were also collected.
2.6. Critical Analysis and Evidence Synthesis
Three authors (MAGM, PRG, SW) designed and developed descriptive questions,
grouped in a matrix format and based on topic areas, to search for evidence-based results
and potential evidence gaps. The question matrix was built by carefully analyzing all the
aspects and topics addressed in the different published diagnostic criteria. The questions
critically appraised for the diagnostic criteria contained in the 4 published proposals can
be found in Table 2. As the topics were identified by us, they were classified—logical and
rational way—within a question, indicating the origin of these criteria. We then examined
whether the individual studies applied these diagnostic criteria during case selection for
their original research. Finally, we subgrouped the selected studies based on the reported
MT rates to low, intermediate and high and manually analyzed whether the authors in each
MT group followed the diagnostic criteria they intended to use. The authorship team subse-
quently synthetized and discussed results and issues to reach consensus for each question.
Evidence-based results were obtained, and potential evidence gaps were noted where
insufficient research evidence exists about a particular topic to make recommendations or
formulate statements.
Table 2. Descriptive questions on proliferative verrucous leukoplakia diagnostic criteria, grouped in a matrix format and
based on topic areas, to search for evidence-based results and potential evidence gaps.
Question 1 Is the clinical course of the disease (persistent or recurrent, periodicity of recurrences) determining inthe PVL diagnosis?
Question 2
To what extent is the age of the lesion decisive for the diagnosis?
Do the studies provide information on the age of the lesions? (follow-up time and/or months of
evolution)
Question 3
What should be the clinical appearance of the lesions to make a diagnosis of proliferative verrucous
leukoplakia?
Were the clinical descriptions made by the authors of the lesions included in their incorporated
cohorts?
Question 4
Is it necessary the for the affection of gingiva and/or palate to make the diagnosis of proliferative
verrucous leukoplakia?
Were the anatomical affectations per patient reported from the included cohorts?
Question 5
Is it necessary to demonstrate malignant transformation to make the diagnosis of proliferative
verrucous leukoplakia?
Were the malignant transformation proportions reported in the included cohorts?
Question 6 Is resistance to treatment necessary to make the diagnosis of proliferative verrucous leukoplakia?
Question 7 To what extent is sex required to make the diagnosis of proliferative verrucous leukoplakia?Was the number of females and males reported in the included cohorts?
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Table 2. Cont.
Question 8 To what extent is age required to make the diagnosis of proliferative verrucous leukoplakia?Was the age of patients reported in the included cohorts?
Question 9
To what extent is tobacco use or its absence necessary to make the diagnosis of proliferative
verrucous leukoplakia?
Was number of smokers and non-smokers reported in the included cohorts?
Question 10
Is the histological study necessary for the diagnosis of proliferative verrucous leukoplakia?
What should be the histological substrate required to make the diagnosis of proliferative verrucous
leukoplakia?
Were the histological descriptions reported by the authors of the lesions analyzed incorporated in
their cohorts?
3. Results
3.1. Results of the Literature Search
The flow diagram (Figure 1) depicts the results obtained in the study identification and
selection process. A total of 750 publications were retrieved: 244 from Web of Science, 174
from Embase, 171 from Scopus, 161 from PubMed and 1 handsearching the reference lists.
After duplicates removal, 341 records were considered potentially eligible and screened
according to titles and abstracts, leaving a sample of 49 studies for full text evaluation.
Finally, 24 studies meeting all eligibility criteria were included for critical analysis and
evidence synthesis in our scoping review [4,6–10,13,21–37].
Figure 1. Flow diagram of the identification and selection process of the studies included in this scoping review.
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3.2. Study Characteristics
Table 3 summarizes the characteristics of the 24 selected studies, which reported on a
total of 631 patients with PVL. Sample sizes ranged between 3 and 81 patients. The studies
were conducted in Europe (n = 12; UK [n = 6], Spain [n = 3], Italy [n = 2], and France
[n = 1]), Asia (n = 3; India [n = 1], Israel [n = 1], and Malaysia [n = 1]), North America
(n = 7; all in USA), South America (n = 1; from Brazil) and one multicentric international
study (Brazil–USA). In relation to diagnostic criteria, 7 studies followed Hansen’s criteria,
2 studies Cerero-Lapiedra’s criteria, 2 studies Villa’s criteria, 1 study Carrard’s criteria,
8 studies used their own criteria, and 4 studies did not report their criteria. According to
their study design, 23 were retrospective cohorts and only one was prospective.
3.3. Critical Analysis and Evidence Synthesis
The results related to the answers to the research questions posed in this scoping
review are shown in Table 4. It refers to the extent to which the four proposals that
published diagnostic criteria consider these research questions as important. In Table 5
we list the number of studies that published malignant transformation of PVL that had
considered these research questions relevant for the diagnosis of PVL in the patients
included in their series. Table 5 also offers the results on the number of individual patients
included in the total series on the aspects collected in the research questions. Among
the most relevant of the published results, it stands out that most studies consider that
PVL should be a white (data reported by 6/24 studies [25%]; 141/141 patients [100%]),
multifocal (data reported by 6/24 studies [25%]; 74/81 patients [91.36%]) and progressive
(data reported by 3/24 studies [12.5%]; 36/51 patients [70.59%]), with a high rate of
malignant transformation (squamous cell carcinoma: 18/24 studies [75%], 139/472 patients
[29.45%]; verrucous carcinoma: 16/24 studies [66.67%], 81/384 patients [21.09%]; papillary
carcinoma: 3/24 studies, 21/98 patients [21.43%]) that appears mainly around 60 years of
age (23/24 studies [95.83%], 556 patients, mean of means = 63.06 years) (Table 5).
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Table 4. Research questions considered in this scoping review, grouped in a matrix format, according to the essential
thematic areas, and results related to the aforementioned questions raised in the evidence derived from the research on
malignant transformation of PVL. The table shows how the four proposals recommended use of these items in their
proposed diagnostic criteria. (yes—green/no—red answer).








Q1 - Is the clinical course of the disease (persistent or recurrent,periodicity of recurrences) determining in the PVL diagnosis? Yes No No No
Q2 - To what extent is the age of the lesion decisive for the PVLdiagnosis? No Yes Yes No
Q3
- What should be the clinical appearance of the lesions to make a
diagnosis of PVL? Yes Yes Yes Yes
Clinical descriptions of the PVL lesions made by the authors:
White plaque Yes Yes Yes Yes
Multifocality Yes Yes Yes Yes
Progressive/expansive nature Yes Yes Yes Yes
Verrucous-like No No Yes No
Erythematous areas Yes No No Yes
Ulcerated areas No No No Yes
Fissured appearance No No No Yes
Smooth appearance No Yes No No
Q4
- Is it necessary the affectation of gingiva and/or palate to make the
diagnosis of PVL? No Yes Yes No
Intraoral sites affected by PVL lesions:
Buccal Mucosa No No No No
Gingiva No Yes Yes No
Tongue No No No No
Palate No Yes Yes No
Q5
- Is it necessary to demonstrate malignant transformation to make the
diagnosis of PVL? Yes Yes Yes Yes
- Malignant transformation reported Yes Yes Yes Yes
Q6 - Is resistance to treatment necessary to make the diagnosis of PVL? Yes No Yes No
Q7
- To what extent is sex required to make the diagnosis of PVL? No Yes No No
Description per sex:
Females No Yes No No
- To what extent is age required to make the diagnosis of PVL? No No No No
Q8 Description of age reported No No No No
Q9
- To what extent is tobacco use or its absence necessary to make the
diagnosis of PVL? No Yes No No
Description for smoking habit:
Non-smokers No Yes No No
Q10
- Is the histological study necessary for the diagnosis of PVL? Yes Yes Yes Yes
Description of alterations in histology of PVL:
Hyperkeratosis Yes Yes No Yes
Atrophy No No No Yes
Acanthosis No No No Yes
Lymphocytic infiltrate in the lamina propria No No No Yes
Verrucous hyperplasia Yes Yes No Yes
Epithelial dysplasia Yes No No Yes
Verrucous carcinoma Yes Yes No No
Papillary carcinoma Yes No No No
Squamous cell carcinoma Yes Yes No Yes
NA, not applicable; NR, not reported.
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Table 5. Research questions considered in this scoping review, grouped in a matrix format, according to the essential
thematic areas, and results related to the aforementioned questions raised in the evidence derived from the research on
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Cerero-Lapiedra
et al. (2010) [11]
Carrard et al.
(2013) [12]
5/24 (20.83%) NR NR
Q3
- What should be the clinical appearance of the lesions to
make a diagnosis of PVL? All NA NA NA
Clinical descriptions of the PVL lesions made by the authors:
White plaque
All 6/24 (25%) 141 141 (100%)
Multifocality All 6/24 (25%) 81 74 (91.36%)
Progressive/expansive nature All 3/24 (12.5%) 51 36 (70.59%)




Villa et al. (2018)
[13]
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Ulcerated areas Villa et al. (2018)[13] 2/24 (8.33%) 11 1 (9.09%)
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make the diagnosis of PVL?
Cerero-Lapiedra
et al. (2010) [11]
Carrard et al.
(2013) [12]
1/24 (4.17%) NA NA
Intraoral sites affected by PVL lesions:
Buccal Mucosa
None 10/24 (41.67%) 145 63 (43.45%)
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et al. (2010) [11]
Carrard et al.
(2013) [12]
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et al. (2010) [11]
Carrard et al.
(2013) [12]
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Q5
- Is it necessary to demonstrate malignant transformation to
make the diagnosis of PVL? All 0/24 (0%) *** NA NA
- Malignant transformation reported All 24/24 (100%) 631 266 (43.74%)
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- To what extent is age required to make the diagnosis of
PVL? None 0/24 (0%) NA NA
Description of age reported None 23/24 (95.83%) 556 **** Mean of means =63.06y
Q9
- To what extent is tobacco use or its absence necessary to
make the diagnosis of PVL?
Cerero-Lapiedra
et al. (2010) [11] 2/24 (8.33%) NA NA
Description for smoking habit:Non-smokers Cerero-Lapiedraet al. (2010) [11] 20/24 (83.33%) 463 285 (61.56%)
Q10
- Is the histological study necessary for the diagnosis of PVL? All 16/24 (66.67%) NA NA





et al. (2010) [11]
Villa et al. (2018)
[13]
10/24 (41.67%) 143 101 (70.63%)
Atrophy Villa et al. (2018)[13] 1/24 (4.17%) 15 1 (6.67%)
Acanthosis Villa et al. (2018)[13] 2/24 (8.33%) 18 6 (33.33%)
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NA, not applicable; NR, not reported., * This column reflects which diagnostic criteria for PVL proposed in the literature (Hansen et al. 1985
[10], Cerero-Lapiedra et al. 2010 [11], Carrard et al. 2013 [12] and Villa et al. 2018 [13]; described in Table 1) include the research question
posed. ** Although a specific study may consider the research question posed as one of its diagnostic criteria, in some cases it does not offer
individual data on the patients in its series. *** Although the 24 studies included in the scoping review offer the number of malignant cases
in their series, none consider malignant transformation as a diagnostic criterion for the disease. **** Most of the studies that report data on
age offer the mean of the series, with very few individual patient data on age.
4. Discussion
The PVL malignancy rates reported by the two systematic reviews and meta-analyses
published to date [3,5] indicate a high risk 49.5% and 43.87%, respectively, for this OPMD.
Additionally, evident is a high inter-study variability of the outcomes essentially dependent
on the type of criteria used for diagnosis and the short follow-up of the patients in most of
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the series [5]. A first analysis of our results indicates, as will be seen below, that most of the
24 papers that report rates of PVL malignancy do not fully follow the diagnostic criteria
proposed in the literature [10].
Our first research question refers to what should be the clinical course of a white lesion
of the oral mucosa that would allow it to be classified as a PVL, or otherwise, to exclude it as a
candidate for this diagnosis. Hansen et al. [10] in their descriptive paper on PVL classify
the lesion as persistent, while the remaining three proposals for diagnostic criteria do not.
Only 25% of the papers analyzed in this scoping review (6 out of 24) [7,9,10,21–23] consider
the persistent nature of the lesion as an essential diagnostic criterion, while the remaining
75% (18 of 24) do not refer to this criterion. In our opinion, and derived from our own
clinical experience, PVL should behave as a persistent lesion, as occurring in other forms
of leukoplakia, and this is probably assumed as necessary for the diagnosis by the authors
who do not specifically clarify this clinical characteristic in its description of criteria. There
is no report in the literature on regression of PVL lesions and thus, it seems that the scant
evidence and accumulated experience advise considering PVL as persistent lesion; so, in
our opinion, this characteristic should be made explicit in a conceptual proposal.
The second research question, somehow related to the previous one, refers to the age
of the lesion as decisive in order to reach the diagnosis of PVL. Cerero-Lapiedra et al. [11] and
Carrard et al. [12] point out that the lesions should be at least 5 years old, although in
Cerero’s criteria this aspect is not considered as determining. In the other two criteria
propositions, it is intuited that PVL is probably present for a long time before being
diagnosed, although this aspect is not stated with precision; thus, Hansen et al. [10]
consider PVL as a “form of leukoplakia that begins as a white plaque of hyperkeratosis
that spreads over time and becomes multifocal”, while Villa et al. [13] point out that
“lesions as they progress, expand in size and/or become multifocal over time”. Five out
24 (20.83%) papers included in this scoping review [13,26,27,34,35] consider the age of the
lesion as a determining criterion for the PVL diagnosis, although only McParland and
Warnakulasuriya (2020) [34] and Upadhyaya et al. (2018) [35] report a minimum period of
evolution time—3.4 and 3 years, respectively—to be able to accept the diagnosis of PVL,
while the remaining three studies do not give specific periods of time (Villa et al. 2018 [13],
Borgna et al. 2017 [27], Flores et al. 2016 [26]); 20 papers (83.33%) do not consider the age of
the lesion as a required criterion. We believe that probably implicit in the diagnosis of PVL
is the fact that the lesion must have existed for a period before the diagnosis is given and,
thus, although based on scant evidence, clinicians possibly assume this aspect as necessary
in the diagnosis.
Our third research question refers to the clinical appearance required for the diagnosis of
PVL. Studies providing information on this issue report PVL as a combination of some
of the following appearances: white plaques, progressively extending along the surface
of the oral mucosa, slow growing, multifocal, smooth, fissured, ulcerated, with erythe-
matous, exophytic and/or warty appearance. The four diagnostic proposals published
to date [10–13] consider PVL as white plaque lesions; 6 out of 24 studies (25%) in our
scoping review [8,9,23,28,30,31], which collect information on 141 patients, report 100%
of the PVL as white plaques, while the remaining papers (18 out of 24; 75%) do not give
this information. In our opinion, the consideration of a PVL as a white plaque is a key
fact in the diagnosis, and it should appear in a conceptual proposal or tentative diagnostic
criteria; probably most authors assume that PVL essentially manifest as white plaques,
although this aspect is not expressly detailed in their criteria. Regarding the multifo-
cality of the lesions, the four PVL diagnostic proposals consider this aspect as essential,
although for Cerero-Lapiedra it is a major criterion, even though not required [11]; 6 out
of 24 studies [8,9,23,30,31,35] included in our scoping review (25%) provide information
in this regard, reporting multifocality in 74 of 81 patients (91.36%). In our view, this is a
common form of PVL presentation that should be considered in a conceptual and diag-
nostic criteria proposal, however, it seems logical to assume that multifocal oral mucosa
affectation only develops in PVL after a long evolution time; linked to the multifocality is
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the progressive nature of the PVL, understanding as such the capacity of these lesions to
affect progressively extensive areas of the oral mucosa. In relation to that, all of the four
PVL diagnosis proposals reported consider multifocality as mandatory for the diagnosis;
only 3 out of the 24 papers [8,9,30] included in our study (12.5%) provide information in
this regard, reporting 36/51 patients (70.59%) presented progressive/expansive lesions ex-
tending through large areas of the oral mucosa; in our opinion, the progressive/expansive
nature of PVL is an essential characteristic in the diagnosis of the disease that should
therefore be included in a conceptual or diagnostic criteria proposal, although it is also
evident that only after a long follow-up of the lesions, or by a meticulous clinical history,
this aspect can be revealed. An important fact of the clinical expression of PVL is its verru-
cous appearances in some areas of the affected oral mucosa, in such a way that even this
feature has been used in naming the disease—proliferative verrucous leukoplakia; of the
diagnostic proposals for PVL, only Carrard et al. [12] consider warty areas as mandatory
for the diagnosis; 5 of 24 papers [8,9,23,30,31] included in our scoping review (20.83%)
offer this information, reporting 22 of 61 patients presenting warty areas (36.07%). For
us, warty appearance acquires importance when presented and, in our view, it should be
considered as a supporting diagnostic criterion. Furthermore, it is recognized that PVL
could also develop erythematous areas; only Hansen et al. [10] and Villa et al. [13] consider
red areas as a possible PVL clinical appearance, albeit this is not required for diagnosis;
6 of 24 papers (25%) [8,9,23,28,30,31] found red areas in 16/141 patients (11.35%), this
appearance being an unusual manifestation of the disease. Finally, only 2 of 24 (8.33%) [8,9]
collect the presence of ulcerated areas, which were observed in only one of the 11 cases
included in their series (9.09%), and none of the studies included in our scoping review
refer to the fissured or smooth appearance of the lesions.
Our next research question addresses the extent to which the gingiva or palate are required
to be involved in order to classify a lesion as PVL. In Cerero-Lapiedra’s criteria [11], the gingiva
and palate involvement is considered as a major not mandatory criterion, Carrard et al. [12]
classify the location as suggested but not mandatory, while neither of the two remaining
proposals [10,13] consider this question as a diagnostic criterion; 10/24 papers [8,9,21,
23,24,26,28,31,33,36] analyzed in this scoping review (41.67%) offer data on the location
of the lesions in 145 patients. The oral mucosal site mostly affected in patients with
PVL was buccal mucosa (63/145 patients; 43.45%) followed by gingiva (58/145 patients;
40%), tongue (47/145 patients; 32.41%), and palate (29/145 patients; 13.79%). The results
indicate that the gingiva is a frequent location for PVL lesions, although it is not considered
mandatory for the diagnosis of this OPMD, the tendency to affect the palate is much
less marked. A proposal for diagnostic criteria should not consider gingival or palatal
involvement as a determining criterion, although it should be of diagnostic support,
especially with regard to gingival involvement.
Another research question is related to what extent it is necessary to demonstrate the
malignant transformation of a white lesion in order to consider it as a PVL. All of the four
diagnostic criteria for PVL proposed malignant transformation as a common fact in the
PVL evolution, although not required for diagnosis [10–13]; 100% of studies included in
our current paper (24/24) [4,6–10,13,21–37] also corroborate this proposition, i.e., no study
indicates malignancy as a mandatory criterion for diagnosis. Papers published in this
regard by the WHO Collaborating Center for Oral Cancer [5] describe PVL as an aggressive
form of leukoplakia, among other reasons due to its tendency to become malignant and to
develop multiple carcinomas. We have reported that perhaps the malignant rate of PVL,
close to 50% of the cases [1,5], could be underestimated due to inconsistent criteria used
for diagnosis; thus, in our previous paper [5] it was shown that studies carried out with
high methodological quality reported significantly higher malignant transformation rates.
Furthermore, an underestimation of the malignancy rate is expected as a consequence of the
short follow-up periods of patients in the series published [5], what seems logical because
this irreversible and persistent OPMD could, at least theoretically, become malignant at
any moment along its evolution. Thus, one might wonder what the reported malignant
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transformation rate for PVL would be if all patients in all series had been followed for life.
From what has been commented, it should be concluded that the high risk of oral cancer
in PVL should be clearly indicated in a conceptual proposition, which will reinforce the
message that must necessarily be translated, i.e., PVL must be carefully followed to achieve
an early diagnosis of the more than probable phenomenon of malignancy.
We also considered to what extent it is necessary for the PVL diagnosis its resistance to any
form of treatment, understanding as such the lesion recurrence/reappearance after treatment.
Two of the four proposals for diagnostic criteria for PVL published consider resistance to
treatment as a mandatory criterion [10,12], while Cerero-Lapiedra [11] propose it as a major
not mandatory criterion. Only two papers (8.33%) [30,32] of those analyzed in this scoping
review report data on treatment recurrence. Garcia-Pola et al. (2016) consider recurrence
to treatment as a mandatory criterion, therefore, reporting 100% of recurrences (14 recur-
rences), while Garcia-Chias et al. (2014) consider it as a major but not mandatory criterion,
reporting 25% of recurrences (10 recurrences in 40 treated PVLs). Recently, a systematic
review and meta-analysis on PVL recurrence after treatment has been published [38]; the re-
sults are conclusive, 232/397 patients treated for PVL (pooled proportion, 67.2%), especially
applying surgical excision with a cold scalpel or laser, recurred after treatment. It should
be noted that the mean follow-up period reported in this meta-analysis was 6 years, which
in practical terms could be considered sufficient to pick up any recurrence. In our opinion,
the scientific evidence on this matter, although scarce, advises considering resistance to
treatment as a support criterion to be included in a conceptual and diagnostic proposal.
Another of our research questions refers to the extent to which the sex and age of patients
are decisive for the diagnosis of PVL. In relation to sex, among the published diagnostic criteria,
only Cerero-Lapiedra [11] considers the female affectation as a non-required minor criterion;
23 of 24 studies [4,6–10,13,21–36] included in this scoping review (95.83%) reported data
in relation to sex; 346/556 (62.23%) patients, for whom information is available, were
women. The result clearly indicates that males and females are affected by the disease in a
very similar way, and therefore, sex should not be considered as a mandatory diagnostic
criterion. Regarding age, no author has proposed an age range as a diagnostic requirement.
None of the published diagnostic criteria consider age as a determining factor for diagnosis;
23 out of 24 studies [4,6–10,13,21–36] included in our scoping review (95.83%) report data
in relation to age, with the mean age of the patients in the published series ranging from
40.3 to 80.8 years, being 63.06 years the mean of means. From what has been published it
can be concluded that PVL develops primarily in the second half of life, around 60 years of
age, and therefore, in our opinion, this information should appear in a conceptual proposal,
also behaving as a diagnostic support criterion.
We also considered to what extent the absence of recognizable etiological factors, essentially
tobacco use, is decisive in the diagnosis of PVL. Only Cerero-Lapiedra et al. [11] consider
the absence of tobacco consumption as a minor non-mandatory criterion, while none of
the remaining proposals refer to this aspect; 20/24 studies [7–10,13,21–27,29–32,34–37]
included in our analysis (83.33%) reported data in relation to tobacco consumption, thus,
178 out of a total of 463 patients with PVL (38.44%) were smokers, from which it can be
concluded that smoking habit is frequent in PVL patients and its absence should not be
considered as a diagnostic criterion.
Among our research questions, finally is whether histopathological analysis of the le-
sions is necessary to make the diagnosis of PVL. All the proposals for the PVL diagno-
sis [10–13] consider the histological study of the tissue as a mandatory criterion and
16 of the 24 studies (66.67%) [4,7,9,10,13,21,23,25–27,29–32,35,36] of the scoping review
consider the histopathological analyses to be decisive to reach the diagnosis of a PVL.
The histopathological data reported by these 16 studies that address this aspect are:
hyperkeratosis—reported by 10 of 24 studies [13,21,23–26,30–33]—which is present in
101 of 143 patients included in their series (70.63%); atrophy—reported by one study [26]—
that appeared in one patient out of a total of 15 (6.67%); acanthosis—reported by 2/24
studies [25,26]—which was found in 6 out of 18 patients (33.33%); lymphocytic infiltrate
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in the chorion, with a band arrangement—reported by 2 of 24 studies [23,31] in 3 of 10
patients (30%); verrucous hyperplasia—reported by 7 of 24 studies [8,9,13,23,31,32,36]
in 38 of 87 patients included in their series (43.68%); epithelial dysplasia—reported
by 10 of 24 studies [13,21,24,26,28,30–32,34,36] in 159 of 274 patients (58.03%); verru-
cous carcinoma, reported by 16 of 24 studies [9,10,13,21–27,30–32,35–37] in 81 of 384 pa-
tients (21.09%); papillary squamous carcinoma—reported by 3 of 24 studies [10,27,35]
in 21 of 98 patients (21.43%); finally, squamous carcinoma—reported by 18 of 24 stud-
ies [4,8–10,13,21–27,30–32,35–37] in 139 of 472 patients (29.45%). As can be deduced from
the results presented, the most common histological events are hyperkeratosis, epithelial
dysplasia, verrucous hyperplasia, as well as the different forms of squamous carcinomas
that are present; 21.09% of oral cancer in PVL are verrucous carcinomas, which are less
aggressive, and so the prognosis of these patients could presumably be favorable. Future
studies focused on this aspect should be conducted to offer results on the prognosis of car-
cinomas in these patients based on a higher quality of evidence. In our view, the inclusion
of the histopathological study in the recommended procedures for the diagnosis of PVL is
justified by the high frequency of epithelial dysplasia and malignant transformation of the
lesions, although it is debatable that one or a set of histological features may be specific
or highly suggestive of PVL, and it is generally recommended that histologic analyses
could serve as diagnostic support in cases of compatible signs and to diagnose malignancy
or evaluate the presence of dysplasia. Recently, an experts group with the support and
approval of the American Academy of Oral and Maxillofacial Pathology and the North
American Society of Head and Neck Pathologists has published a consensus guide to
the histological features in PVL [39]. In this guide, four categories were considered to
standardize and report the histopathological findings of PVL, namely: (1) “corrugated
ortho (para) hyperkeratotic lesion, not reactive”; (2) “bulky hyperkeratotic epithelial pro-
liferation, not reactive”; (3) “suspicious for” or “squamous cell carcinoma”; (4) “does not
fit any above category”. Contrary to what we observed in our scoping review, in which
epithelial dysplasia appeared in 58% of patients, the authors of this consensus guide report,
without referring to any bibliographic citations, that the presence of epithelial dysplasia is
a rare occurrence.
The potential limitations of the present scoping review are truly inherent to the
primary-level studies investigated, being essentially the low sample sizes of most of the
studies—which is fully justified given the low incidence of PVL—and the scarcity of data
reported to answer some of the questions formulated (e.g., clinical appearance of PVL
lesions). Future studies should make a comprehensive report of the characteristics of their
patients, and the questions formulated by us could serve as a reporting checklist for the
authors of future studies so as not to forget the approach to some essential aspects that
should not be denied in the investigation of this OPMD. The main strength of our study
is fundamentally due to its originality, this being the first scoping review that offers to
address the diagnostic criteria of PVL in a holistic way and based on scientific evidence.
5. Conclusions
In conclusion, it is worth asking what a PVL is, or in other words, what clinicopatho-
logical aspects should be included in a concept proposal. In our view, and taking into
account what was previously stated in the discussion, a PVL is an oral potentially malignant
disorder that presents in the form of multifocal white plaques, which have expanded throughout
its evolution, persistent and resistant to treatment, which is diagnosed in people in the second half
of life, although it probably begins in earlier stages, and which has a very high risk of developing
oral cancer. We must recognize that this concept only partially modifies, based on the
evidence, the concept initially proposed by Hansen et al. [10], authors who demonstrated
great insight in their initial analysis of this lesion. As can be deduced from our reflections in
the discussion, some of the aspects of this conceptual proposition are based on the available
evidence—i.e., the expansive behavior, the persistence of the lesions and their resistance
to treatment—and require a long follow-up of the patients or the information extracted
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from a meticulous medical history. It should also be specified that from the histological
analysis one should not wait to obtain specific facts of this entity, although it is essential
to assess the presence of dysplasia and diagnose—early—cancer in suspicious areas. It is
also important to think over when a clinician is authorized to make an accurate diagnosis
of PVL on the first visit. The issue is transcendent since it implies assuming a very high
risk of cancer and implementing specific management measures, including information
to the patient. In our opinion, only exhaustive compliance with all the aspects included
in our conceptual proposal, some of which must be extracted from the patient’s medical
history, will allow to reach the maximum level of diagnostic certainty. Otherwise, it would
be interesting to reflect on the level of certainty with which we made our diagnosis in those
cases of less certain diagnosis. Thus, for example, an intermediate level of certainty could
correspond to white lesions in patients in the second half of life, not too extensive, in which
their recurrence after treatment and their expansive nature throughout their evolution
have been demonstrated. A low level of certainty could correspond to white lesions that
appear in the second half of life, essentially affecting a small limited area of the oral mucosa,
with small incipient lesions appearing in other remote locations. It is evident that it is
impossible to establish clinical facts that precisely define the diagnostic certainty levels of
PVL since these are largely based on the experience of the clinician, although some facts
could reinforce our level of certainty, i.e., the presence of warty areas and perhaps gingival
involvement; however, we believe that it is necessary to reflect on the extent to which
the diagnosis of PVL becomes important among the possibilities of presumed diagnosis
of a white lesion, since as we commented, this implies establishing follow-up protocols
and specific patient information. From what has been discussed so far, it is also deduced
that it is very difficult, if not impossible, to establish a proposal of diagnostic criteria that
encompasses all the possibilities with which a PVL can present itself from the beginning.
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